Harvard Bioscience (HBIO) Inventory Average (2011 - 2026)

Harvard Bioscience (HBIO) has reported Inventory Average for 16 consecutive years, with $22.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Inventory Average fell 1.41% year-over-year to $22.2 million in Q2 2026; TTM through Jun 2026 was $22.2 million, a 1.41% decrease from a year earlier, with the FY2025 full-year figure at $22.0 million, down 8.15% from the prior year.
• Inventory Average was $22.2 million for Q2 2026 at Harvard Bioscience, up from $21.5 million in the prior quarter.
• Over five years, Inventory Average peaked at $29.0 million in Q2 2022 and troughed at $21.2 million in Q4 2025.
• A 5-year average of $24.8 million and a median of $25.0 million in 2023 frame the typical range for Inventory Average.
• Across the five-year window, Inventory Average gained 25.28% in 2022 and declined 14.2% in 2025, its largest moves.
• Over 5 years, Inventory Average stood at $26.3 million in 2022, then slipped by 3.85% to $25.3 million in 2023, then dropped by 2.57% to $24.6 million in 2024, then dropped by 13.86% to $21.2 million in 2025, then grew by 4.78% to $22.2 million in 2026.
• The last three Inventory Average figures came in at $22.2 million (Q2 2026), $21.5 million (Q1 2026), and $21.2 million (Q4 2025), per Business Quant data.